tiprankstipranks
Trending News
More News >
Arovella Therapeutics Limited (AU:ALA)
ASX:ALA
Advertisement

Arovella Therapeutics Limited (ALA) Price & Analysis

Compare
13 Followers

ALA Stock Chart & Stats


Arovella Therapeutics Limited News

ALA FAQ

What was Arovella Therapeutics Limited’s price range in the past 12 months?
Arovella Therapeutics Limited lowest share price was AU$0.07 and its highest was AU$0.21 in the past 12 months.
    What is Arovella Therapeutics Limited’s market cap?
    Arovella Therapeutics Limited’s market cap is AU$124.80M.
      When is Arovella Therapeutics Limited’s upcoming earnings report date?
      Arovella Therapeutics Limited’s upcoming earnings report date is Aug 27, 2025 which is in 25 days.
        How were Arovella Therapeutics Limited’s earnings last quarter?
        Currently, no data Available
        Is Arovella Therapeutics Limited overvalued?
        According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Arovella Therapeutics Limited pay dividends?
          Arovella Therapeutics Limited does not currently pay dividends.
          What is Arovella Therapeutics Limited’s EPS estimate?
          Arovella Therapeutics Limited’s EPS estimate is >-0.01.
            How many shares outstanding does Arovella Therapeutics Limited have?
            Arovella Therapeutics Limited has 1,188,566,400 shares outstanding.
              What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Arovella Therapeutics Limited?
              Currently, no hedge funds are holding shares in AU:ALA

              Arovella Therapeutics Limited Stock Smart Score

              Company Description

              Arovella Therapeutics Limited

              Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.

              Arovella Therapeutics Limited (ALA) Earnings & Revenues

              Currently, no data available
              Please return soon. This page is being updated.
              Similar Stocks
              Company
              Price & Change
              Follow
              Amplia Therapeutics
              Alterity Therapeutics
              Proteomics International Laboratories Ltd.
              EZZ Life Science Holdings Ltd.
              Recce Pharmaceuticals Ltd.

              Ownership Overview

              1.02%98.98%
              Mutual Funds
              ― Other Institutional Investors
              98.98% Public Companies and
              Individual Investors

              Options Prices

              Currently, No data available
              ---
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis